Uterotonic drugs in obstetric bleeding prevention and treatment

Abstract

One of the main causes of maternal mortality is obstetric bleeding, among which 2/3 of cases are bleeding in the early postpartum period. The existing methods of preventing and stopping uterine bleeding in the postpartum period do not always allow achieving the desired result due to the ineffectiveness of the measures taken. The aim of this study was to assess the effectiveness of existing uterotonic drugs in the obstetric bleeding prevention and treatment. We performed a detailed systematic analysis of modern domestic and foreign literature on uterotonic drugs being used to prevent and stop obstetric bleeding, with their main parameters considered. The study used such information databases as eLIBRARY.RU, Scopus, PubMed, MEDLINE, ScienceDirect, and Cochrane Library from inception to December 2020. Despite a significant number of studies devoted to exploring the possibilities of uterotonic drugs, currently there are no methods with absolute therapeutic efficacy, which requires research to develop new drugs based on their synthetic analogues.

Keywords

postpartum hemorrhage / uterotonics / oxytocin / misoprostol / ergot alkaloids / side effects

References

[1] Maswime S, Buchmann E. A systematic review of maternal near miss and mortality due to postpartum hemorrhage. Int J Gynaecol Obstet. 2017;137(1):1–7. doi: 10.1002/ijgo.12096

[2] Maswime S., Buchmann E. A systematic review of maternal near miss and mortality due to postpartum hemorrhage // Int. J. Gynaecol. Obstet. 2017. Vol. 137. No. 1. P. 1–7. doi: 10.1002/ijgo.12096

[3] Baev OR, Davydov AI. Poslerodovoe krovotechenie: akusherskaya taktika i intensivnaya terapiya. Voprosy ginekologii, akusherstva i perinatologii. 2011;10(6):65–69. (In Russ.)

[4] Баев О.Р., Давыдов А.И. Послеродовое кровотечение: акушерская тактика и интенсивная терапия // Вопросы гинекологии, акушерства и перинатологии. 2011. Т. 10. № 6. С. 65–69.

[5] Ziganshin AM, Mudrov VA, Lyapunov AK. Determination of the volume of early hypotonic hemorrhage by 3d modeling of ultrasound investigation results. Biomedical Engineering. 2020;54(3):169–173. doi: 10.1007/s10527-020-09997-z

[6] Ziganshin A.M., Mudrov V.A., Lyapunov A.K. Determination of the volume of early hypotonic hemorrhage by 3d modeling of ultrasound investigation results // Biomedical Engineering. 2020. Vol. 54. No. 3. P. 169–173. doi: 10.1007/s10527-020-09997-z

[7] Nyfløt LT, Sandven I, Stray-Pedersen B, et al. Risk factors for severe postpartum hemorrhage: A case-control study. BMC Pregnancy Childbirth. 2017;17(1):17. doi: 10.1186/s12884-016-1217-0

[8] Nyfløt L.T., Sandven I., Stray-Pedersen B. et al. Risk factors for severe postpartum hemorrhage: a case-control study // BMC Pregnancy Childbirth. 2017. Vol. 17. No. 1. P. 17. doi: 10.1186/s12884-016-1217-0

[9] WHO recommendations: uterotonics for the prevention of postpartum haemorrhage. Geneva: World Health Organization; 2018 [¬cited 19 Jan 2021]. Available from: https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420-eng.pdf?ua=1

[10] WHO recommendations: uterotonics for the prevention of postpartum haemorrhage. Geneva: World Health Organization, 2018 [дата обращения: 19.01.2021]. Доступ по ссылке: https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420-eng.pdf?ua=1

[11] Yarmolinskaya MI, Khobets VV. The role of oxytocin in the pathogenesis of endometriosis: various aspects of the problem. Journal of obstetrics and women’s diseases. 2019;68(3):89-98. (In Russ.). doi: 10.17816/JOWD68389-98

[12] Ярмолинская М.И., Хобец В.В. Роль окситоцина в патогенезе эндометриоза: различные грани проблемы // Журнал акушерства и женских болезней. 2019. Т. 68. № 3. С. 89–98. doi: 10.17816/JOWD68389-98

[13] Tsirkin VI, Trukhina SI, Trukhin AN, Anisimov KYu. Oxytocin receptors (literature review). Pt. 1. Vestnik Ural’skoi Medi-tsinskoi Akademicheskoi Nauki. 2018;15(3):470–475. (In Russ.). doi: 10.22138/2500-0918-2018-15-3-470-487

[14] Циркин В.И., Трухина С.И., Трухин А.Н., Анисимов К.Ю. Окситоциновые рецепторы (обзор литературы). Часть 1 // Вестник Уральской медицинской академической науки. 2018. Т. 15. № 3. С. 470–475. doi: 10.22138/2500-0918-2018-15-3-470-487

[15] Kimura T, Takemura M, Nomura S, et al. Expression of oxytocin receptor in human pregnant myometrium. Endocrinology. 1996;137(2):780–785. doi: 10.1210/endo.137.2.8593830

[16] Kimura T., Takemura M., Nomura S. et al. Expression of oxytocin receptor in human pregnant myometrium // Endocrinology. 1996. Vol. 137. No. 2. P. 780–785. doi: 10.1210/endo.137.2.8593830

[17] Fuchs AR, Fuchs F, Husslein P, et al. Oxytocin receptors in the human uterus during pregnancy and parturition. Am J Obstet Gynecol. 1984;150(6):734–741. doi: 10.1016/0002-9378(84)90677-x

[18] Fuchs A.R., Fuchs F., Husslein P. et al. Oxytocin receptors in the human uterus during pregnancy and parturition // Am. J. Obstet. Gynecol. 1984. Vol. 150. No. 6. P. 734–741. doi: 10.1016/0002-9378(84)90677-x

[19] Yulia A, Johnson MR. Myometrial oxytocin receptor expression and intracellular pathways. Minerva Ginecol. 2014;66(3):267–280.

[20] Yulia A., Johnson M.R. Myometrial oxytocin receptor expression and intracellular pathways // Minerva Ginecol. 2014. Vol. 66. No. 3. P. 267–280.

[21] Robinson C, Schumann R, Zhang P, Young RC. Oxytocin-induced desensitization of the oxytocin receptor. Am J Obstet Gynecol. 2003;188(2):497–502. doi: 10.1067/mob.2003.22

[22] Robinson C., Schumann R., Zhang P., Young R.C. Oxytocin-induced desensitization of the oxytocin receptor // Am. J. Obstet. Gynecol. 2003. Vol. 188. No. 2. P. 497–502. doi: 10.1067/mob.2003.22

[23] Tsirkin VI, Trukhina SI, Trukhin AN, Anisimov KYu. Oxytocin receptors (literature review). Pt. 2. Vestnik Ural’skoi Medi-tsinskoi Akademicheskoi Nauki. 2018;15(3):625–640. (In Russ.). doi: 10.22138/2500-0918-2018-15-4-625-640

[24] Циркин В.И., Трухина С.И., Трухин А.Н., Анисимов К.Ю. Окситоциновые рецепторы. (Обзор литературы). Часть 2 // Вестник Уральской медицинской академической науки. 2018. Т. 15. № 4. С. 625–640. doi: 10.22138/2500-0918-2018-15-4-625-640

[25] Heesen M, Carvalho B, Carvalho JCA, et al. International consensus statement on the use of uterotonic agents during caesarean section. Anaesthesia. 2019;74(10):1305–1319. doi: 10.1111/anae.14757

[26] Heesen M., Carvalho B., Carvalho J.C.A. et al. International consensus statement on the use of uterotonic agents during caesarean section // Anaesthesia. 2019. Vol. 74. No. 10. P. 1305–1319. doi: 10.1111/anae.14757

[27] Seng J. Posttraumatic oxytocin dysregulation: Is it a link among posttraumatic self disorders, posttraumatic stress disorder, and pelvic visceral dysregulation conditions in women? J Trauma Dissociation. 2010;11(4):387–406. doi: 10.1080/15299732.2010.496075

[28] Seng J. Posttraumatic oxytocin dysregulation: Is it a link among posttraumatic self disorders, posttraumatic stress disorder, and pelvic visceral dysregulation conditions in women? // J. Trauma Dissociation. 2010. Vol. 11. No. 4. P. 387–406. doi: 10.1080/15299732.2010.496075

[29] Alotaibi MF. Effects of intermittent and continuous oxytocin exposure on myometrial contractile activity in term-pregnant rats in vitro. Reprod Sci. 2020;27(4):1024–1029. doi: 10.1007/s43032-019-00104-6

[30] Alotaibi M.F. Effects of intermittent and continuous oxytocin exposure on myometrial contractile activity in term-pregnant rats in vitro // Reprod. Sci. 2020. Vol. 27. No. 4. P. 1024–1029. doi: 10.1007/s43032-019-00104-6

[31] Talati C, Carvalho JCA, Luca A, Balki M. The effect of intermittent oxytocin pretreatment on oxytocin-induced contractility of human myometrium in vitro. Anesth Analg. 2019;128(4):671–678. doi: 10.1213/ANE.0000000000002834

[32] Talati C., Carvalho J.C.A., Luca A., Balki M. The effect of intermittent oxytocin pretreatment on oxytocin-induced contractility of human myometrium in vitro // Anesth. Analg. 2019. Vol. 128. No. 4. P. 671–678. doi: 10.1213/ANE.0000000000002834

[33] Balki M, Ramachandran N, Lee S, Talati C. The recovery time of myometrial responsiveness after oxytocin-induced desensitization in human myometrium in vitro. Anesth Analg. 2016;122(5):1508–1515. doi: 10.1213/ANE.0000000000001268

[34] Balki M., Ramachandran N., Lee S., Talati C. The recovery time of myometrial responsiveness after oxytocin-induced desensitization in human myometrium in vitro // Anesth. Analg. 2016. Vol. 122. No. 5. P. 1508–1515. doi: 10.1213/ANE.0000000000001268

[35] Wu Y, Wang H, Wu QY, et al. A meta-analysis of the effects of intramuscular and intravenous injection of oxytocin on the third stage of labor. Arch Gynecol Obstet. 2020;301(3):643–653. doi: 10.1007/s00404-020-05467-9

[36] Wu Y., Wang H., Wu Q.Y. et al. A meta-analysis of the effects of intramuscular and intravenous injection of oxytocin on the third stage of labor // Arch. Gynecol. Obstet. 2020. Vol. 301. No. 3. P. 643–653. doi: 10.1007/s00404-020-05467-9

[37] Adnan N, Conlan-Trant R, McCormick C, et al. Intramuscular versus intravenous oxytocin to prevent postpartum haemorrhage at vaginal delivery: randomised controlled trial. BMJ. 2018;362:k3546. doi: 10.1136/bmj.k3546

[38] Adnan N., Conlan-Trant R., McCormick C. et al. Intramuscular versus intravenous oxytocin to prevent postpartum haemorrhage at vaginal delivery: randomised controlled trial // BMJ. 2018. No. 362. P. k3546. doi: 10.1136/bmj.k3546

[39] Degtyarev EN, Shifman EM, Tikhova GP, et al. Oxytocin as a risk factor for developing myocardial ischemia. Gyneco-logy, Obstetrics and Perinato¬logy. 2018;17(4):5–10. (In Russ.). doi: 10.20953/1726-1678-2018-4-5-10

[40] Дегтярев Е.Н., Шифман Е.М., Тихова Г.П. и др. Окситоцин как фактор риска развития ишемии миокарда // Вопросы гинекологии, акушерства и перинатологии. 2018. Т. 17. № 4. С. 5–10. doi: 10.20953/1726-1678-2018-4-5–10

[41] Rabow S, Olofsson P. Pulse wave analysis by digital photoplethysmography to record maternal hemodynamic effects of spinal anesthesia, delivery of the baby, and intravenous oxytocin during cesarean section. J Matern Fetal Neonatal Med. 2017;30(7):759–766. doi: 10.1080/14767058.2016.1186162

[42] Rabow S., Olofsson P. Pulse wave analysis by digital photoplethysmography to record maternal hemodynamic effects of spinal anesthesia, delivery of the baby, and intravenous oxytocin during cesarean section // J. Matern. Fetal Neonatal. Med. 2017. Vol. 30. No. 7. P. 759–766. doi: 10.1080/14767058.2016.1186162

[43] Pantoja T, Abalos E, Chapman E, et al. Oxytocin for preventing postpartum haemorrhage (PPH) in non-facility birth settings. Cochrane Database Syst Rev. 2016;4:CD011491. doi: 10.1002/14651858.CD011491.pub2

[44] Pantoja T., Abalos E., Chapman E. et al. Oxytocin for preventing postpartum haemorrhage (PPH) in non-facility birth settings // Cochrane Database Syst. Rev. 2016. No. 4. P. CD011491. doi: 10.1002/14651858.CD011491.pub2

[45] Rabow S, Hjorth U, Schönbeck S, Olofsson P. Effects of oxytocin and anaesthesia on vascular tone in pregnant women: A randomised double-blind placebo-controlled study using non-invasive pulse wave analysis. BMC Pregnancy Childbirth. 2018;18(1):453. doi: 10.1186/s12884-018-2029-1

[46] Rabow S., Hjorth U., Schönbeck S., Olofsson P. Effects of oxytocin and anaesthesia on vascular tone in pregnant women: a randomised double-blind placebo-controlled study using non-invasive pulse wave analysis // BMC Pregnancy Childbirth. 2018. Vol. 18. No. 1. P. 453. doi: 10.1186/s12884-018-2029-1

[47] Kovacheva VP, Soens MA, Tsen LC. A randomized, double-blinded trial of a “Rule of Threes” algorithm versus continuous infusion of oxytocin during elective cesarean delivery. Anesthesiology. 2015;123(1):92–100. doi: 10.1097/ALN.0000000000000682

[48] Kovacheva V.P., Soens M.A., Tsen L.C. A randomized, double-blinded trial of a “Rule of Threes” algorithm versus continuous infusion of oxytocin during elective cesarean delivery // Anesthesiology. 2015. Vol. 123. No. 1. P. 92–100. doi: 10.1097/ALN.0000000000000682

[49] Voskresenskiy SL. Shilkina EV, Zelenko EN, Fedoseeva NA. Giperstimuljacija matochnoj aktivnosti – faktor riska gipoksii ploda i novorozhdennogo. Reproduktivnoe zdorov’e. Vostochnaya Evropa. 2012;2(5):255–258. (In Russ.)

[50] Воскресенский C.Л., Шилкина Е.В., Зеленко Е.Н., Федосеева Н.А. Гиперстимуляция маточной активности — фактор риска гипоксии плода и новорожденного // Репродуктивное здоровье. Восточная Европа. 2012. Т. 23. № 5. С. 255–258.

[51] Shifman EM, Kulikov AV, Krugova LV, et al. Safety of uterotonics: what anaesthesiologist should know about them? Anaesthesiology and Reanimatology. 2017;62(3):220–224. (In Russ.). doi: 10.18821/0201-7563-2017-62-3-220-224

[52] Шифман Е.М., Куликов А.В., Кругова Л.В. и др. Безопасность применения утеротоников: что должен знать анестезиолог-реаниматолог? // Анестезиология и реаниматология. 2017. Т. 62. № 3. С. 220–224. doi: 10.18821/0201-7563-2017-62-3-220-224

[53] Cardaillac C, Rua C, Simon EG, El-Hage W. L’ocytocine et la dépression du post-partum [Oxytocin and postpartum depression]. J Gynecol Obstet Biol Reprod (Paris). 2016;45(8):786–795. doi: 10.1016/j.jgyn.2016.05.002

[54] Cardaillac C., Rua C., Simon E.G., El-Hage W. L’ocytocine et la dépression du post-partum [Oxytocin and postpartum depression] // J. Gynecol. Obstet. Biol. Reprod (Paris). 2016. Vol. 45. No. 8. P. 786–795. doi: 10.1016/j.jgyn.2016.05.002

[55] De Winter S, Vanbrabant P, Vi NT, et al. Impact of temperature exposure on stability of drugs in a real-world out-of-hospital setting. Ann Emerg Med. 2013;62(4):380–387. doi: 10.1016/j.annemergmed.2013.04.018

[56] De Winter S., Vanbrabant P., Vi N.T. et al. Impact of temperature exposure on stability of drugs in a real-world out-of-hospital setting // Ann. Emerg. Med. 2013. Vol. 62. No. 4. P. 380–387. doi: 10.1016/j.annemergmed.2013.04.018

[57] World Health Organization. Oxytocin: adopted text for the international pharmacopoeia: final text for addition to the international pharmacopoeia (June 2010). 4th ed. Geneva: World Health Organization; 2010 [cited 19 Jan 2021]. Available from: https://docplayer.net/23855577-Oxytocin-adopted-text-for-the-international-pharmacopoeia-final-text-for-addition-to-the-international-pharmacopoeia-june-2010.html

[58] World Health Organization. Oxytocin: adopted text for the international pharmacopoeia: final text for addition to the international pharmacopoeia (June 2010). 4th ed. Geneva: World Health Organization; 2010 [дата обращения: 19.01.2021]. Доступ по ссылке: https://docplayer.net/23855577-Oxytocin-adopted-text-for-the-international-pharmacopoeia-final-text-for-addition-to-the-international-pharmacopoeia-june-2010.html

[59] Torloni MR, Gomes Freitas C, Kartoglu UH, et al. Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature. BJOG. 2016;123(13):2076–2086. doi: 10.1111/1471-0528.13998

[60] Torloni M.R., Gomes Freitas C., Kartoglu U.H. et al. Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature // BJOG. 2016. Vol. 123. No. 13. P. 2076–2086. doi: 10.1111/1471-0528.13998

[61] Zhu C, Estrada M, White J, Lal M. Heat-stable sublingual oxytocin tablets as a potential needle-free approach for preventing postpartum hemorrhage in low-resource settings. Drug Deliv Transl Res. 2018;8(3):853–856. doi: 10.1007/s13346-017-0471-7

[62] Zhu C., Estrada M., White J., Lal M. Heat-stable sublingual oxytocin tablets as a potential needle-free approach for preventing postpartum hemorrhage in low-resource settings // Drug Deliv. Transl. Res. 2018. Vol. 8. No. 3. P. 853–856. doi: 10.1007/s13346-017-0471-7

[63] Hagen N, Bizimana T, Kayumba PC, et al. Stability of oxytocin preparations in Malawi and Rwanda: stabilizing effect of chlorobutanol. Am J Trop Med Hyg. 2020;103(5):2129–2141. doi: 10.4269/ajtmh.20-0255

[64] Hagen N., Bizimana T., Kayumba P.C. et al. Stability of oxytocin preparations in Malawi and Rwanda: stabilizing effect of chlorobutanol // Am. J. Trop. Med. Hyg. 2020. Vol. 103. No. 5. P. 2129–2141. doi: 10.4269/ajtmh.20-0255

[65] World Health Organisation. Quality of misoprostol products. WHO Drug Inf. 2016;30(1):35-39 [cited 19 Jan 2021]. Available from: https://www.who.int/medicines/publications/druginformation/WHO_DI_30-1_Quality.pdf?ua=1

[66] World Health Organisation. Quality of misoprostol products // WHO Drug Inf. 2016. Vol. 30. No. 1. P. 35–39 [дата обращения: 19.01.2021]. Доступ по ссылке: https://www.who.int/medicines/publications/druginformation/WHO_DI_30-1_Quality.pdf?ua=1

[67] Malm M, Madsen I, Kjellström J. Development and stability of a heat-stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle-income countries. J Pept Sci. 2018;24(6):e3082. doi: 10.1002/psc.3082

[68] Malm M., Madsen I., Kjellström J. Development and stability of a heat-stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle-income countries // J. Pept. Sci. 2018. Vol. 24. No. 6. P. e3082. doi: 10.1002/psc.3082

[69] Muggleton E. Oxytocin study raises concerns about carbetocin use. Anesthesia and Analgesia. 2018;126(4):1423. doi: 10.1213/ANE.0000000000002710

[70] Muggleton E. Oxytocin study raises concerns about carbetocin use // Anesthesia and Analgesia. 2018. Vol. 126. No. 4. P. 1423. doi: 10.1213/ANE.0000000000002710

[71] Cole NM, Carvalho JC, Erik-Soussi M, et al. In vitro comparative effect of carbetocin and oxytocin in pregnant human myometrium with and without oxytocin pretreatment. Anesthesiology. 2016;124(2):378–386. doi: 10.1097/ALN.0000000000000940

[72] Cole N.M., Carvalho J.C., Erik-Soussi M. et al. In vitro comparative effect of carbetocin and oxytocin in pregnant human myometrium with and without oxytocin pretreatment // Anesthesiology. 2016. Vol. 124. No. 2. P. 378–386. doi: 10.1097/ALN.0000000000000940

[73] Voon HY, Suharjono HN, Shafie AA, Bujang MA. Carbetocin versus oxytocin for the prevention of postpartum hemorrhage: A meta-ana¬lysis of randomized controlled trials in cesarean deliveries. Taiwan J Obstet Gynecol. 2018;57(3):332–339. doi: 10.1016/j.tjog.2018.04.002

[74] Voon H.Y., Suharjono H.N., Shafie A.A., Bujang M.A. Carbetocin versus oxytocin for the prevention of postpartum hemorrhage: A meta-analysis of randomized controlled trials in cesarean deliveries // Taiwan J. Obstet. Gynecol. 2018. Vol. 57. No. 3. P. 332–339. doi: 10.1016/j.tjog.2018.04.002

[75] Amornpetchakul P, Lertbunnaphong T, Boriboonhiransarn D, et al. Intravenous carbetocin versus intravenous oxytocin for preventing atonic postpartum hemorrhage after normal vaginal delivery in high-risk singleton pregnancies: a triple-blind randomized controlled trial. Arch Gynecol Obstet. 2018;298(2):319–327. doi: 10.1007/s00404-018-4806-5

[76] Amornpetchakul P., Lertbunnaphong T., Boriboonhiransarn D. et al. Intravenous carbetocin versus intravenous oxytocin for preventing atonic postpartum hemorrhage after normal vaginal delivery in high-risk singleton pregnancies: a triple-blind randomized controlled trial // Arch. Gynecol. Obstet. 2018. Vol. 298. No. 2. P. 319–327. doi: 10.1007/s00404-018-4806-5

[77] Ronenson AM, Shifman EM, Kulikov AV. Pregrady na puti rutinnogo primeneniya karbetotsina. Vestnik akusherskoy anesteziologii. 2020;6(32):14–15 [cited 2021 Jan 19]. Available from: https://www.arfpoint.ru/wp-content/uploads/2020/07/32_06_2020.pdf. (In Russ.). doi: 10.24411/2686-8032-2020-00017

[78] Роненсон А.М., Шифман Е.М., Куликов А.В. Преграды на пути рутинного применения карбетоцина // Вестник акушерской анестезиологии. 2020. № 6(32). С. 14–15 [дата обращения: 19.01.2021]. Доступ по ссылке: https://www.arfpoint.ru/wp-content/uploads/2020/07/32_06_2020.pdf. doi: 10.24411/2686-8032-2020-00017

[79] Widmer M, Piaggio G, Nguyen TMH, et al.; WHO CHAMPION Trial Group. Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth. N Engl J Med. 2018;379(8):743–752. doi: 10.1056/NEJMoa1805489

[80] Widmer M., Piaggio G., Nguyen T.M.H. et al; WHO CHAMPION Trial Group. Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth // N. Engl. J. Med. 2018. Vol. 379. No. 8. P. 743–752. doi: 10.1056/NEJMoa1805489

[81] Babloyan AG, Tsakhilova SG, Sakvarelidze NYu, et al. Profilaktika akusherskikh krovotecheniy u patsientok grupp vysokogo riska. Sovremennaya lechebnaya taktika. Problemy reproduktsii. 2019;25(5):100–109. (In Russ.). doi: 1017116/repro201925051

[82] Баблоян А.Г., Цахилова С.Г., Сакварелидзе Н.Ю. и др. Профилактика акушерских кровотечений у пациенток групп высокого риска. Современная лечебная тактика // Проблемы репродукции. 2019. Т. 25. № 5. С. 100–109. doi: 1017116/repro201925051

[83] James AH, Cooper DL, Paidas MJ. Hemostatic assessment, treatment strategies, and hematology consultation in massive postpartum hemorrhage: results of a quantitative survey of obstetrician-gynecologists. Int J Womens Health. 2015;7:873–881. doi: 10.2147/IJWH.S89573

[84] James A.H., Cooper D.L., Paidas M.J. Hemostatic assessment, treatment strategies, and hematology consultation in massive postpartum hemorrhage: results of a quantitative survey of obstetrician-gynecologists // Int. J. Womens Health. 2015. Vol. 7. P. 873–881. doi: 10.2147/IJWH.S89573

[85] Klinicheskie rekomendatsii (protokol lecheniya) № 15-4/10/2-2535 “Profilaktika, algoritm vedeniya, anesteziya i intensivnaya terapiya pri poslerodovykh krovotecheniyakh”, utverzhdennye Ministerstvom zdravookhraneniya Rossiyskoy Federatsii 26 March 2019 [cited 2021 Jan 19]. Available from: https://www.garant.ru/products/ipo/prime/doc/72186142/. (In Russ.)

[86] Клинические рекомендации (протокол лечения) № 15-4/10/2-2535 «Профилактика, алгоритм ведения, анестезия и интенсивная терапия при послеродовых кровотечениях», утвержденные Министерством здравоохранения Российской Федерации 26 марта 2019 г. [дата обращения: 19.01.2021]. Доступ по ссылке: https://www.garant.ru/products/ipo/prime/doc/72186142/

[87] Gallos ID, Coomarasamy A. Carbetocin: Worth the extra expense? Best Pract Res Clin Obstet Gynaecol. 2019;61:55–65. doi: 10.1016/j.bpobgyn.2019.04.001

[88] Gallos I.D., Coomarasamy A. Carbetocin: worth the extra expense? // Best Pract. Res. Clin. Obstet Gynaecol. 2019. Vol. 61. P. 55–65. doi: 10.1016/j.bpobgyn.2019.04.001

[89] Abediasl Z, Sheikh M, Pooransari P, et al. Vaginal misoprostol versus intravenous oxytocin for the management of second-trimester pregnancies with intrauterine fetal death: A randomized clinical trial. J Obstet Gynaecol Res. 2016;42(3):246–251. doi: 10.1111/jog.12910

[90] Abediasl Z., Sheikh M., Pooransari P. et al. Vaginal misoprostol versus intravenous oxytocin for the management of second-trimester pregnancies with intrauterine fetal death: A randomized clinical trial // J. Obstet. Gynaecol. Res. 2016. Vol. 42. No. 3. P. 246–251. doi: 10.1111/jog.12910

[91] Momot AP, Molchanova IV, Tskhai BV. Pharmacotherapy for massive obstetric hemorrhage Obstetrics and Gynecology. 2010;4:3–10. (In Russ.)

[92] Момот А.П., Молчанова И.В., Цхай В.Б. Фармакотерапия массивных акушерских кровотечений // Акушерство и гинекология. 2010. № 4. С. 3–10.

[93] Liabsuetrakul T, Choobun T, Peeyananjarassri K, et al. Prophylactic use of ergot alkaloids in the third stage of labour. Cochrane Database Syst Rev. 2018;6(6):CD005456. doi: 10.1002/14651858.CD005456.pub3

[94] Liabsuetrakul T., Choobun T., Peeyananjarassri K. et al. Prophylactic use of ergot alkaloids in the third stage of labour // Cochrane Database Syst. Rev. 2018. Vol. 6. No. 6. P. CD005456. doi: 10.1002/14651858.CD005456.pub3

[95] Birch S, Lu C. Ergometrine-induced atrial fibrillation at caesarean section. BMJ Case Rep. 2019;12(2):e226747. doi: 10.1136/bcr-2018-226747

[96] Birch S., Lu C. Ergometrine-induced atrial fibrillation at caesarean section // BMJ Case Rep. 2019. Vol. 12. No. 2. P. e226747. doi: /10.1136/bcr-2018-226747

[97] Pis’menskiy SV, Pyregov AV, Golubeva OA. Myocardial infraction ater cesarean section under spinal anesthesia during treatment with oxytocin and metilergometrin (clinical observation). Tol’yattinskiy meditsinskiy konsilium. 2016;(5-6):59–62. (In Russ.)

[98] Письменский С.В., Пырегов А.В., Голубева О.А. Инфаркт миокарда после операции кесарева сечения при спинальной анестезии на фоне применения метилэргометрина и окситоцина (клиническое наблюдение) // Тольяттинский медицинский консилиум. 2016. № 5-6. С. 59–62.

[99] Danchin N, Selton-Suty C, Juilliere Y, et al. Methylergometrine-induced coronary artery spasm causing total occlusion of all three coronary arteries. Eur Heart J. 1990;11(12):1127–1129. doi: 10.1093/oxfordjournals.eurheartj.a059655

[100] Danchin N., Selton-Suty C., Juilliere Y. et al. Methylergometrine-induced coronary artery spasm causing total occlusion of all three coronary arteries // Eur. Heart J. 1990. Vol. 11. No. 12. P. 1127–1129. doi: 10.1093/oxfordjournals.eurheartj.a059655

[101] Bilgin Z, Kömürcü N. Comparison of the effects and side effects of misoprostol and oxytocin in the postpartum period: A systematic review. Taiwan J Obstet Gynecol. 2019;58(6):748–756. doi: 10.1016/j.tjog.2019.09.004

[102] Bilgin Z., Kömürcü N. Comparison of the effects and side effects of misoprostol and oxytocin in the postpartum period: A systematic review // Taiwan J. Obstet. Gynecol. 2019. Vol. 58. No. 6. P. 748–756. doi: 10.1016/j.tjog.2019.09.004

[103] Aziz S, Kazi S, Haq G, Soomro N. Oral misoprostol versus oxytocin in the management of third stage of labour. J Pak Med Assoc. 2014;64(4):428–432

[104] Aziz S., Kazi S., Haq G., Soomro N. Oral misoprostol versus oxytocin in the management of third stage of labour // J. Pak Med. Assoc. 2014. Vol. 64. No. 4. P. 428–432.

[105] Radzinsky VE, Kostin IN, Savenkova IV. Misoprostol — prevention and treatment of postpartum hemorrhage (based on FIGO–2018 Congress). Obstetrics and Gynecology: News, Opinions, Training. 2018;6:30–33. (In Russ.). doi: 10.24411/2303-9698-2018-13904

[106] Радзинский В.Е., Костин И.Н., Савенкова И.В. Мизопростол – профилактика и лечение послеродовых кровотечений (по материалам Конгресса FIGO – 2018) // Акушерство и гинекология: Новости. Мнения. Обучения. 2018. Т. 6. № 3. С. 30–33. doi: 10.24411/2303-9698-2018-13904

[107] Yaju Y, Kataoka Y, Eto H, et al. Prophylactic interventions after delivery of placenta for reducing bleeding during the postnatal period. Cochrane Database Syst Rev. 2013;(11):CD009328. doi: 10.1002/14651858.CD009328.pub2

[108] Yaju Y., Kataoka Y., Eto H. et al. Prophylactic interventions after delivery of placenta for reducing bleeding during the postnatal period // Cochrane Database Syst. Rev. 2013. No. 11. P. CD009328. doi: 10.1002/14651858.CD009328.pub2

[109] Tan J, Cao Q, He GL, et al. Misoprostol versus ergometrine-oxytocin for preventing postpartum haemorrhage: a systematic review and meta-analysis of randomized controlled trials. J Evid Based Med. 2016;9(4):194–204. doi: 10.1111/jebm.12201

[110] Tan J., Cao Q., He G.L. et al. Misoprostol versus ergometrine-oxytocin for preventing postpartum haemorrhage: a systematic review and meta-analysis of randomized controlled trials // J. Evid. Based Med. 2016. Vol. 9. No. 4. P. 194–204. doi: 10.1111/jebm.12201

[111] Mavrides E, Allard S, Chandraharan E, et al. On behalf of the Royal College of Obstetricians and Gynaecologists. Prevention and management of postpartum haemorrhage. BJOG. 2016;124(5):e106–e149. doi: 10.1111/1471-0528.14178

[112] Mavrides E., Allard S., Chandraharan E. et al. On behalf of the Royal College of Obstetricians and Gynaecologists. Prevention and management of postpartum haemorrhage // BJOG. 2016. Vol. 124. No. 5. P. e106-e149. doi: 10.1111/1471-0528.14178

[113] Sinchikhin SP, Sarbasova AE, Mamiev OB, Stepanyan LV. Prevention of increased blood loss during caesarean section: current aspects. Obstetrics and Gynecology. 2018;(4):16–20. (In Russ.). doi: 10.18565/aig.2018.4.16-20

[114] Синчихин С.П., Сарбасова А.Е., Мамиев О.Б., Степанян Л.В. Современные аспекты профилактики повышенной кровопотери при кесаревом сечении // Акушерство и гинекология. 2018. № 4. С. 16–20. doi: 10.18565/aig.2018.4.16-20

RIGHTS & PERMISSIONS

Eсо-Vector